Compiled 2026-09-26Data through 2025-12-282 min read
Dated source-based research · No live market data

Executive summary

Annual revenue of USD 94.193 billion and net income of USD 26.804 billion for the period ended 2025-12-28. This is a structured data brief from filed financial statements, not an independently audited investment opinion.

Business and industry context

JOHNSON & JOHNSON is an SEC-reporting issuer listed on NYSE under JNJ. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications. Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Financial evidence

The selected fiscal period runs from 2024-12-30 to 2025-12-28. Revenue was USD 94.193 billion; operating income was not available; diluted EPS was USD 11.03 per share. Prior-period revenue was USD 88.821 billion. The reported revenue change was 6.05%. Comparisons are not adjusted for acquisitions, disposals, foreign exchange or fiscal-week differences.

Profitability and cash generation

Net margin, calculated as net income divided by revenue, was 28.46%. Operating cash flow was USD 24.530 billion; capital expenditure was USD 4.832 billion. Free cash flow (operating cash flow less purchases of property, plant and equipment) was USD 19.698 billion. Missing standard tags are not interpreted as zero. These measures may not be directly comparable between business models.

Balance-sheet context

Total assets were USD 199.210 billion, total liabilities USD 117.666 billion and reported shareholder equity not available at the period end. Total liabilities include operating obligations and are not a measure of interest-bearing debt.

Valuation context

This release does not include a synchronized market-price dataset. Consequently, price-based multiples are not quoted. P/E requires a dated share price and a clearly identified EPS basis; P/S and P/B require consistently dated capitalization and accounting denominators. A multiple alone does not establish fair value.

Risks and uncertainties

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration. Standardized XBRL can omit custom-tag disclosures. Annual data cannot establish the direction of the latest quarter.

What to monitor

Product concentration, research investment, utilization, reimbursement and cash generation. Read subsequent quarterly filings, footnotes and accounting-policy changes before interpreting these historical observations.

Methodology note

Source snapshots were collected on September 18, 2026. Values preserve reported currency and periods. This brief was compiled on September 26, 2026; the publication date is not a new source retrieval date.

Sources & dates